Key result
The single-pill combination of perindopril, indapamide, and amlodipine provides effective blood pressure control with similar efficacy to the separate pills, reducing pill burden and potentially improving adherence.
Why the study?
Complex treatment regimens and high pill burden reduce adherence and BP control in patients with hypertension requiring three antihypertensive agents.
Does a single-pill combination of perindopril, indapamide, and amlodipine improve blood pressure control and adherence compared to free combinations or dual therapies in patients with hypertension?
Does a single-pill combination of perindopril, indapamide, and amlodipine improve blood pressure control and adherence compared to free combinations or dual therapies in patients with hypertension?
The single-pill combination of perindopril, indapamide, and amlodipine is an effective and convenient option that simplifies treatment regimens for patients with hypertension requiring three drugs.
May support convenient triple SPC use in controlled hypertension; leaves open need for randomized outcome confirmation.
The single-pill combination (SPC) of perindopril (PER)/indapamide (IND)/amlodipine (AML) is a valuable and convenient treatment option for patients with hypertension controlled with two-drug SPC of PER/IND + AML given as two separate pills at the same dose level. PER [an angiotensin-converting enzyme (ACE) inhibitor], IND (a thiazide-like diuretic) and AML (a calcium channel blocker) are well established antihypertensive agents, which have been available for a long time as monotherapies and dual SPCs and have complementary mechanisms of action. Once-daily PER/IND/AML provided effective BP control, with good tolerability, in patients with uncontrolled hypertension in clinical trials and in large observational prospective studies. The efficacy and tolerability of PER/IND/AML was similar to that of PER/IND + AML in a randomized clinical trial. The therapeutic effect of PER/IND/AML was associated with improved health-related quality of life. Thus, switching from the two-pill PER/IND + AML regimen to single-pill PER/IND/AML reduces pill burden and simplifies drug administration, which may improve adherence to treatment, leading to better BP control and clinical outcomes. Approximately one-quarter of patients with hypertension require three antihypertensive agents to achieve BP control. However, complex treatment regimens and high pill burden reduce treatment adherence, which in turn leads to poor BP control. Perindopril (PER), indapamide (IND), amlodipine (AML) belong to the core drug classes for the treatment of hypertension. These drugs have been available for a long time as monotherapies and two-drug single-pill combinations. Once-daily PER/IND/AML provides very good BP control in patients with uncontrolled hypertension and is generally well tolerated. The single-pill PER/IND/AML has similar efficacy and tolerability to PER/IND + AML given as two separate pills. Therefore, switching from PER/IND + AML to PER/IND/AML reduces pill burden and simplifies the treatment regimen, which may improve adherence to treatment, leading to better BP control and clinical outcomes. Thus, PER/IND/AML is a valuable and convenient treatment option for patients with hypertension controlled with PER/IND + AML at the same dose level.
No takes yet. Share an insight, caveat, or question.
Yahiya Y. Syed (2022) conducted a review in Hypertension. Perindopril/Indapamide/Amlodipine single-pill combination vs. Perindopril/Indapamide + Amlodipine (separate pills) or free combinations was evaluated. The single-pill combination of perindopril, indapamide, and amlodipine provides effective blood pressure control with similar efficacy to the separate pills, reducing pill burden and potentially improving adherence.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: